The estimated Net Worth of Stephen M. Mc Lean is at least $461 millier dollars as of 19 August 2022. Stephen Lean owns over 20,000 units of Certara stock worth over $461,160 and over the last 4 years Stephen sold CERT stock worth over $0.
Stephen has made over 2 trades of the Certara stock since 2020, according to the Form 4 filled with the SEC. Most recently Stephen bought 20,000 units of CERT stock worth $326,400 on 19 August 2022.
The largest trade Stephen's ever made was buying 22,000 units of Certara stock on 15 December 2020 worth over $506,000. On average, Stephen trades about 21,000 units every 306 days since 2020. As of 19 August 2022 Stephen still owns at least 42,000 units of Certara stock.
You can see the complete history of Stephen Lean stock trades at the bottom of the page.
Stephen's mailing address filed with the SEC is C/O ARSENAL CAPITAL PARTNERS, 100 PARK AVENUE, 31ST FLOOR, NEW YORK, NY, 10017.
Over the last 5 years, insiders at Certara have traded over $2,048,278,243 worth of Certara stock and bought 97,245 units worth $1,908,085 . The most active insiders traders include Avatar Parent L.P.Eqt Avata..., James E Iii Cashman et Mason P Slaine. On average, Certara executives and independent directors trade stock every 14 days with the average trade being worth of $7,828,136. The most recent stock trade was executed by Leif E Pedersen on 9 September 2024, trading 51,224 units of CERT stock currently worth $578,319.
Certara Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinincal and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software and technology to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, and Australia. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
Certara executives and other stock owners filed with the SEC include: